Wolff Wiese Magana’s Protagonist Therapeutics PTGX Stock Holding History

Wolff Wiese Magana’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.29K	Hold	35	–	–	﹤0.01%	677
2026 Q1	$3.69K	Hold	35	–	–	﹤0.01%	668
2025 Q4	$3.06K	Hold	35	–	–	﹤0.01%	676
2025 Q3	$2.33K	Hold	35	–	–	﹤0.01%	731
2025 Q2	$1.94K	Hold	35	–	–	﹤0.01%	732
2025 Q1	$1.69K	Hold	35	–	–	﹤0.01%	756
2024 Q4	$1.35K	Hold	35	–	–	﹤0.01%	769
2024 Q3	$1.57K	Buy	+35	New	+$1.41K	﹤0.01%	779

Other funds holding PTGX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Wolff Wiese Magana's PTGX Position: Q2 2026 in Review

Wolff Wiese Magana held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 35 shares worth $4.29K. The position accounts for ﹤0.01% of the portfolio, ranked #677.

Wolff Wiese Magana first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. 69 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Wolff Wiese Magana held 35 shares of Protagonist Therapeutics worth $4.29K as of Q2 2026.
Wolff Wiese Magana left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up ﹤0.01% of Wolff Wiese Magana's portfolio in Q2 2026, its #677 holding.
Wolff Wiese Magana first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
69 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Wolff Wiese Magana's 13F filing for Q2 2026, filed 13 Jul 2026.